By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
BLX-7006 pill: what Biolexis will show at the American obesity congress
The BLX-7006 pill is a new experimental obesity drug that has just reached its first trial in people. The US company Biolexis will present the data at ObesityWeek, the American obesity congress that opens on November 14 in Washington. In this first trial, the pill was safe and well tolerated. There were also early signs of weight loss. Keep in mind: this is an investigational drug that regulators have not approved.
Alongside it, another company will present a lab-stage pill that boosts energy burning. Here are the key points, plus what you can already do today.
What makes the BLX-7006 pill different
Most GLP-1 drugs act on the receptor at the same spot as the natural hormone. The BLX-7006 pill, by contrast, attaches to a different pocket near the receptor’s outer surface. The researchers showed this with high-resolution molecular imaging (Cryo-EM, cryo-electron microscopy).
In other words, the pill does not compete with the natural hormone. Instead, it amplifies its signal. In lab tests on cells, combining it with natural GLP-1 or with semaglutide boosted the signal inside the cell about 3-fold. It is a small-molecule pill you swallow, like other experimental GLP-1 pills.
How the researchers built the first trial in people
The trial included 77 healthy adults and compared the pill with placebo. The researchers tested single rising doses, the effect of food, and repeated doses. Doses ranged from 25 to 150 mg. In the repeated-dose part, participants took the pill once a day for 7 days.
First, the researchers looked at how the body handles the drug. The body absorbed the pill quickly, and it peaked in the blood after about 2 hours. Its half-life was 9 to 10 hours. Food did not meaningfully change absorption. So the company expects people could take it once a day.
Safety results of the BLX-7006 pill
The pill was well tolerated at all doses. There were no serious side effects, and no participant stopped treatment. All treatment-related side effects were mild to moderate.
What’s more, digestive side effects were few. Nausea occurred in 4.2% of those on the pill, versus 5.9% on placebo. Diarrhea occurred in 2.1%, versus 5.9%. No one reported vomiting. During the week of repeated dosing, any digestive side effect occurred in 20.8% of those on the pill, versus 44.4% on placebo.
Early signals on weight and blood sugar
The trial did not aim to measure weight loss, so these are only early signals. Even so, the share of participants who lost weight rose with the dose. At 25 mg, 33% lost weight. At 150 mg, 83% lost weight, versus 38% on placebo. On average, weight went down in those on the pill and up in those on placebo.
In addition, blood sugar two hours after the dose was lower than with placebo. The company did not publish exact numbers for this. Also, the trial lasted only one week and enrolled healthy volunteers without obesity.
Next step: a 12-week trial of the BLX-7006 pill
The company plans a 12-week follow-up trial. It will include people with obesity, with and without type 2 diabetes. The trial will look at safety, as well as early effects on weight and blood sugar control. Biolexis also has a second experimental drug, BLX-0871, designed to protect muscle during weight loss.
From the lab: a pill that boosts energy burning
At the congress, the London company Mitotech will also present data on MT-1101, an experimental once-daily pill. Unlike most drugs, it does not work mainly on appetite. Instead, it speeds up fat burning in the mitochondria, the cell’s power plants.
The data come from an animal model of obesity and include a comparison with semaglutide. In other words, no one has tested the pill in people yet, and the announcement included no numbers. The company is aiming for use alongside GLP-1 drugs, to protect muscle and to help keep weight off after treatment stops. I covered other early developments from the congress, such as a once-weekly pill and a once-a-quarter injection, in my article on Kailera’s new drugs.
What the BLX-7006 pill means for you
The BLX-7006 pill is still far from the pharmacy. A one-week trial in healthy volunteers is only the first step. Still, two things are encouraging. First, the pill caused little nausea. Second, its mechanism is new compared with current drugs.
Ultimately, the trend is clear. Companies are looking for convenient pills, new ways of working and drugs that protect muscle. All of this could make treatment much easier and more accessible in the future.
What you can do today
There is no need to wait for the drugs of the future. Effective, approved treatments already exist, as injections and as pills. For example, Foundayo and the Wegovy pill are approved pills for obesity. Injections such as Wegovy and Mounjaro are also available in Israel. If you are considering treatment, talk to a doctor who specializes in obesity care.
It is also important to protect your muscle while losing weight. A protein-rich diet and strength training help with this. I also wrote about preventing muscle loss.
Bottom line
The BLX-7006 pill was safe and well tolerated in its first trial in people, with few digestive side effects. The signals on weight and blood sugar are interesting, but very early. Meanwhile, Mitotech is presenting a new direction from the lab: boosting energy burning. I will update you when trials in people report data. In the meantime, current treatments already work, and they are worth starting with medical guidance.
This article is general information and is not personal medical advice. Always consult your doctor before changing your treatment.
References
Mitotech to Present New Data on Oral Obesity Treatment Candidate MT-1101 at ObesityWeek® 2026
These data come from the companies’ press releases, which came out before the full poster presentations at the congress.
